NorthWest Biotherapeutics Inc (NWBO)

[antihama]

Here's the transcription (99% accurate)

@1:06 What else we can do w these images….Radionomics is a relatively new tech in imagining. Quantitative molecular imaging provides a potential platform for linking specific imaging traits w a specific gene expression patterns and these imaging features may actually serve as molecular surrogates that contribute to diagnosis, prognosis, and likely gene expression associated treatment response. So here’s a pt on TKI… these pts didn’t have the classic response pattern. Certainly, not the debt of response that was accessed but actually the tumors became ghosted and this is a way of looking at the individual pixels in here to define a response phenotype based upon on certain futures in this basically the graying of the tumor…
Potentially w the exact same scans that we have we MAY be able to distinguish between true progression and pseudo based upon on the patterns that we actually see in the individual pixels on the same imaging set.
So in conclusion what we need is better data collection of the actual images in the appropriate meta data and this should include images that were obtained post progression, that’s absolutely critical. We need to standardize iRECIST, as a 1st step w very specific rules of response and progression and then we also have to enhance the data collection so that our case report forms are more robust and complete. For instance, just beginning w the basic concept of report - all the sites of disease and all the different methods that we see progression. And we should explore alternatives - Radionomics is one that I briefly touched upon solely because it’s available, it’s actually available on the actual images. @1:08:35